Intra-Cellular Shares Owned by Institutions

ITCI
 Stock
  

USD 55.17  1.91  3.35%   

Intra-Cellular Ther fundamentals help investors to digest information that contributes to Intra-Cellular Ther's financial success or failures. It also enables traders to predict the movement of Intra-Cellular Stock. The fundamental analysis module provides a way to measure Intra-Cellular Ther's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Intra-Cellular Ther stock. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  
Refresh

Intra-Cellular Shares Owned by Institutions Analysis

Intra-Cellular Ther's Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
 2021 2022 (projected)
Interest Expense33.1 K33.97 K
Gross Profit75.77 M81.75 M
Shares Held by Institutions 
 = 
Funds and Banks 
Firms 
More About Shares Owned by Institutions | All Equity Analysis

Current Intra-Cellular Ther Shares Owned by Institutions

    
  86.56 %  
Most of Intra-Cellular Ther's fundamental indicators, such as Shares Owned by Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Intra-Cellular Ther is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Intra-Cellular Shares Owned by Institutions Driver Correlations

Understanding the fundamental principles of building solid financial models for Intra-Cellular Ther is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Shares Owned by Institutions. Since Intra-Cellular Ther's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Intra-Cellular Ther's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Intra-Cellular Ther's interrelated accounts and indicators.
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Compare to competition

Based on the latest financial disclosure, 86% of Intra-Cellular Ther are shares owned by institutions. This is 93.91% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The shares owned by institutions for all United States stocks is 120.76% lower than that of the firm.

Intra-Cellular Shares Owned by Institutions Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Intra-Cellular Ther's direct or indirect competition against its Shares Owned by Institutions to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Intra-Cellular Ther could also be used in its relative valuation, which is a method of valuing Intra-Cellular Ther by comparing valuation metrics of similar companies.
Intra-Cellular Ther is currently under evaluation in shares owned by institutions category among related companies.

Intra-Cellular Ther Current Valuation Drivers

We derive many important indicators used in calculating different scores of Intra-Cellular Ther from analyzing Intra-Cellular Ther's financial statements. These drivers represent accounts that assess Intra-Cellular Ther's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Intra-Cellular Ther's important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Net Income Per Employee(2 M)(2.13 M)(447.64 K)(591.09 K)(554.93 K)(598.74 K)
Revenue Per Employee7.85 K5.02 K18459.4 K163.68 K176.6 K
Average Assets381.88 M400.13 M296.14 M602.7 M586.77 M498.29 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(98.62 M)(154.76 M)(147.24 M)(226.46 M)(283.59 M)(291.05 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(98.62 M)(154.76 M)(147.24 M)(226.46 M)(283.59 M)(291.05 M)
Earnings before Tax(98.83 M)(155.13 M)(147.72 M)(226.99 M)(284.12 M)(291.6 M)
Average Equity366.64 M371.23 M241.82 M544.06 M517.6 M443.81 M
Enterprise Value737.94 M553.56 M1.82 B2.28 B4.18 B4.51 B
Free Cash Flow(81.22 M)(118.56 M)(128.68 M)(230.34 M)(259.87 M)(266.71 M)
Invested Capital419.49 M265.96 M130.47 M648.16 M368.21 M332.89 M
Invested Capital Average333.71 M306.89 M193.88 M423.85 M451.48 M372.11 M
Market Capitalization790.28 M623.33 M1.9 B2.55 B4.26 B4.6 B
Tangible Asset Value471.49 M357.21 M251.19 M717.31 M489.92 M435.39 M
Working Capital455.01 M319.14 M194.1 M654.05 M413.92 M379.9 M

Intra-Cellular Ther Institutional Holders

Institutional Holdings refers to the ownership stake in Intra-Cellular Ther that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Intra-Cellular Ther's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Intra-Cellular Ther's value.
Security TypeSharesValue
Fmr LlcCommon Shares11 M670.3 M
Vanguard Group IncCommon Shares7.8 M476.6 M
Wasatch Advisors IncCommon Shares7.5 M457.6 M
Blackrock IncCommon Shares6.5 M395.9 M
Wellington Management Group LlpCommon Shares4.1 M248.5 M
Bellevue Group AgCommon Shares3.4 M209.9 M
Marshall Wace LlpCommon Shares2.5 M154.2 M

Intra-Cellular Fundamentals

About Intra-Cellular Ther Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Intra-Cellular Ther's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intra-Cellular Ther using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intra-Cellular Ther based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun for the treatment of Parkinsons disease and heart failure ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Intra-Cellular Ther Investors Sentiment

The influence of Intra-Cellular Ther's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Intra-Cellular. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Intra-Cellular Ther Implied Volatility

    
  67.17  
Intra-Cellular Ther's implied volatility exposes the market's sentiment of Intra-Cellular Ther stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Intra-Cellular Ther's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Intra-Cellular Ther stock will not fluctuate a lot when Intra-Cellular Ther's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Intra-Cellular Ther in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Intra-Cellular Ther's short interest history, or implied volatility extrapolated from Intra-Cellular Ther options trading.

Current Sentiment - ITCI

Intra-Cellular Ther Investor Sentiment

Most of Macroaxis users are currently bullish on Intra-Cellular Ther. What is your judgment towards investing in Intra-Cellular Ther? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Intra-Cellular Ther using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Intra-Cellular Ther Piotroski F Score and Intra-Cellular Ther Altman Z Score analysis. Note that the Intra-Cellular Ther information on this page should be used as a complementary analysis to other Intra-Cellular Ther's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Complementary Tools for Intra-Cellular Stock analysis

When running Intra-Cellular Ther price analysis, check to measure Intra-Cellular Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intra-Cellular Ther is operating at the current time. Most of Intra-Cellular Ther's value examination focuses on studying past and present price action to predict the probability of Intra-Cellular Ther's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Intra-Cellular Ther's price. Additionally, you may evaluate how the addition of Intra-Cellular Ther to your portfolios can decrease your overall portfolio volatility.
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Is Intra-Cellular Ther's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intra-Cellular Ther. If investors know Intra-Cellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intra-Cellular Ther listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
5.2 B
Quarterly Revenue Growth YOY
1.2
Return On Assets
-0.25
Return On Equity
-0.43
The market value of Intra-Cellular Ther is measured differently than its book value, which is the value of Intra-Cellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intra-Cellular Ther's value that differs from its market value or its book value, called intrinsic value, which is Intra-Cellular Ther's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intra-Cellular Ther's market value can be influenced by many factors that don't directly affect Intra-Cellular Ther's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intra-Cellular Ther's value and its price as these two are different measures arrived at by different means. Investors typically determine Intra-Cellular Ther value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intra-Cellular Ther's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.